VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress
Posted on: Friday, 1 August 2008, 09:00 CDT
SAN FRANCISCO, Aug. 1 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. , a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that Rebecca A. Taub, MD, VIA's senior vice president of research and development, will present at the 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress taking place August 4-7 in Boston, MA.
The presentation details are as follows: Date/Time: Wednesday, August 6, 2008: 2:20-2:50 p.m. ET Location: World Trade Center Boston & Seaport Hotel Session: Translational Medicine IV: Case Studies of Translational Approaches from Preclinical to Clinical Proof-of-Concept Title: Innovative Clinical Trial and Biomarker Approaches To Demonstrate the Role Of Leukotrienes and 5LO Inhibition in Atherosclerotic Disease
"VIA has taken an innovative approach in its design of Phase 2 clinical trials for VIA-2291, its lead compound," said Dr. Taub. "I am excited to share with conference participants our view on the value of innovative techniques in the design of critical clinical trials, particularly with regards to serum inflammatory biomarkers, analyses of atherosclerotic plaque tissue, and non-invasive imaging."
About VIA Pharmaceuticals, Inc.
VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple Phase 2 clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com/.
VIA Pharmaceuticals, Inc.
CONTACT: James G. Stewart, Senior Vice President and Chief FinancialOfficer of VIA Pharmaceuticals, Inc., +1-415-283-2204; or Media, DanielleBertrand of WeissComm Partners, +1-415-946-1056, dbertrand@wcpglobal.com; orInvestors, San Francisco, Ian Clements, or Lauren Glaser, +1-415-392-3385, orNew York City, Brian Korb, +1-646-378-2923, all of The Trout Group, for VIAPharmaceuticals, Inc.
Web site: http://www.viapharmaceuticals.com/
Source: PRNewswire-FirstCall
Related Articles
- Water Street Healthcare Partners Acquires Pharmaceutical Development Business From AAIPharma Inc.
- Dr. Garratt W. Ponder Named Vice President of Pharmaceutical Development for Atlanta-Based Tikvah Therapeutics, Inc.
- 2006 Nobel Prize Winner to Deliver Keynote Address at IBC's 12th Annual Drug Discovery & Development of Innovative Therapeutics World Congress
- Catalyst Pharmaceutical Partners, Inc. Names Vice President of Pharmaceutical Development and Project Management
- CytRx RNAi Subsidiary, RXi Pharmaceuticals, Names Vice President of Pharmaceutical Development
- Immtech Appoints Carol Ann Olson, MD to Senior Vice President of Pharmaceutical Development and Chief Medical Officer
- Novavax Head of Pharmaceutical Development to Present on Micellar Nanoparticle Technology at Particles 2006 Meeting
- Covalent Group, Inc. Signs $2.2 Million Contract With New Sponsor to Conduct Clinical Trial in Patients With Cardiovascular Disease
- CollaGenex Pharmaceuticals Announces Agreement to Acquire SansRosa Pharmaceutical Development Inc.
- Novavax Appoints New Vice President of Pharmaceutical Development
 |
 |
User Comments (0)
RSS Feeds